GenVec, Inc.
News and overview for GenVec, Inc.
GenVec Signs New Contract to Support HIV and Influenza Vaccine Development [Press Release]
PRNewswire | 18 days 5 hours 21 minutes ago
...5 /PRNewswire-FirstCall/ -- GenVec, Inc. announced today that SAIC-Frederick...currently in clinical testing. GenVec, Inc. is a biopharmaceutical company...Investor Contact: Media Contact: GenVec, Inc. Tiberend Strategic Advisors...
GenVec Reports Third Quarter 2009 Financial Results [Press Release]
PRNewswire | 17 days 20 hours 57 minutes ago
GAITHERSBURG, Md., Nov. 5 /PRNewswire-FirstCall/ -- GenVec, Inc.
GenVec to Present at Merriman Curhan Ford's Investor Summit 2009 [Press Release]
PRNewswire | 20 days 4 hours 27 minutes ago
...PRNewswire-FirstCall/ -- Today GenVec, Inc. announced that Paul H. Fischer...will be accessible for 30 days. GenVec, Inc. is a biopharmaceutical company...Investor Contact: Media Contact: GenVec, Inc. Tiberend Strategic Advisors...
GenVec and SAIC-Frederick signs contract to develop influenza and HIV vaccines
News-Medical.Net | 17 days 18 hours 56 minutes ago
GenVec, Inc. (Nasdaq: GNVC) announced today that SAIC-Frederick, Inc. has signed a contract with GenVec for the development of influenza and HIV vaccines in support of the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). This four-year contract has a total value of over $22 million if all options are exercised. Over the next year, GenVec will receive approximately $2.6 million.
FDA Grants Orphan Drug Designation for TNFerade(TM) [Press Release]
PRNewswire | 19 days 5 hours 30 minutes ago
GenVec Announces Third Quarter 2009 Results Conference Call [Press Release]
PRNewswire | 26 days 7 hours 27 minutes ago
...28 /PRNewswire-FirstCall/ -- GenVec, Inc. announced that it will release...click on "Webcasts and Data." GenVec, Inc. is a biopharmaceutical company...Investor Contact: Media Contact: GenVec, Inc. Tiberend Strategic Advisors...
GenVec receives FDA orphan drug designation for TNFerade
News-Medical.Net | 19 days 9 hours 53 minutes ago
GenVec, Inc. (Nasdaq: GNVC) announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to TNFerade(TM) for the treatment of pancreatic cancer.
GenVec Receives NASDAQ Notice of Minimum Bid Price Non-Compliance [Press Release]
PRNewswire | 68 days 11 hours 41 minutes ago
...FirstCall/ -- On September 15, 2009, GenVec, Inc. received a notice from The NASDAQ...minimum bid price requirement. GenVec, Inc. is a biopharmaceutical company...INVESTOR CONTACT: MEDIA CONTACT: GenVec, Inc. Tiberend Strategic Advisors...
GenVec Receives National Cancer Institute Grant to Expand Cancer Program [Press Release]
PRNewswire | 54 days 12 hours 12 minutes ago
...30 /PRNewswire-FirstCall/ -- GenVec, Inc. announced today that it has received...severely unmet medical need." GenVec, Inc. is a biopharmaceutical company...Investor Contact: Media Contact: GenVec, Inc. Tiberend Strategic Advisors...
GenVec Receives Fourth-Year Funding From NIAID For HIV Vaccine Contract [Press Release]
PRNewswire | 60 days 12 hours 41 minutes ago
...24 /PRNewswire-FirstCall/ -- GenVec, Inc. announced today that the National...adenovirus serotype technology. GenVec, Inc. is a biopharmaceutical company...Investor Contact: Media Contact: GenVec, Inc. Tiberend Strategic Advisors...
GenVec Receives an Approximately $2.5 Million Grant to Support Novel Cell Line Development [Press Release]
PRNewswire | 90 days 12 hours 42 minutes ago
...25 /PRNewswire-FirstCall/ -- GenVec, Inc. announced today that it has received...Director of Vector Sciences. GenVec, Inc. is a biopharmaceutical company...Desk photodesk@prnewswire.com GenVec, Inc. CONTACT: Danielle M. DiPirro...
GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants [Press Release]
PRNewswire | 88 days 12 hours 11 minutes ago
...27 /PRNewswire-FirstCall/ -- GenVec, Inc. announced today that it has entered...solicitation, or sale is unlawful. GenVec, Inc. is a biopharmaceutical company...Desk photodesk@prnewswire.com GenVec, Inc. CONTACT: Danielle M. DiPirro...
GenVec Reports Second Quarter 2009 Financial Results [Press Release]
PRNewswire | 109 days 3 hours 41 minutes ago
GAITHERSBURG, Md., Aug. 6 /PRNewswire-FirstCall/ -- GenVec, Inc.
Research and Markets: Ophthalmic Pharmaceutical Drugs - A Global Market Perspective [Press Release]
Business Wire | 5 days 13 hours 15 minutes ago
Research and Markets (http://www.researchandmarkets.com/research/4e2e61/ophthalmic_pharmac) has announced the addition of the "Ophthalmic Pharmaceutical Drugs - A Global Market Perspective" report to their offering.
VIVALIS ACCELERATES MARKETING OF EB66 CELL LINE IN NORTH AMERICA [Press Release]
MarketWire | 41 days 2 hours 43 minutes ago
NANTES, FRANCE -- (Marketwire) -- 10/13/09 -- VIVALIS (NYSE Euronext Paris: VLS), a biopharmaceutical company that provides the pharmaceutical industry with innovative cell-based solutions for the manufacture of vaccines and proteins and develops drugs to prevent and treat viral diseases, announces today that they executed an agreement with Louis J. Cantolupo to accelerate the marketing of the EB66® cell line in North America, principally in monoclonal antibodies and the therapeutic proteins.
Sign up for ANA SmartBrief
Company Overview
| Company: | GenVec, Inc. |
|---|---|
| Industry: | Biopharmaceuticals & Biotherapeutics |
| Website: | http://www.genvec.com |
GenVec is all over the medical map. The clinical-stage biopharmaceutical firm develops gene-based drugs and vaccines for everything from cancer to HIV. Its lead candidate, TNFerade, may boost the effectiveness of chemotherapy used to treat pancreatic and other types of cancer. Another drug candidate, AdPEDF, is in early clinical testing to treat age-related macular degeneration, a leading cause of blindness. GenVec is also developing multiple vaccines for contagious diseases, such as HIV, malaria, and foot-and-mouth, through grants from and collaborations with several federal agencies: National Institute of Allergy and Infectious Diseases, US Department of Homeland Security, and US Department of Agriculture.
Key Numbers
| Sales in U.S. Dollars (mil.) | 15.1 (2008) |
|---|---|
| One-year % Growth in Sales | 7.6 (2008) |
| Net Income in U.S. Dollars (mil.) | -26.1 (2008) |
| One-year % Growth in Net Income | 0.0 (2008) |
| Number of Employees | 98 (2008) |
| One-year % Growth in Number of Employees | -17.6 (2008) |
| Fiscal Year-End | December |